Inozyme Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INZY research report →
Companywww.inozyme.com
Inozyme Pharma, Inc. , a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
- CEO
- Douglas A. Treco
- IPO
- 2020
- Employees
- 67
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $258.25M
- P/E
- -4.67
- P/S
- 0.00
- P/B
- 8.09
- EV/EBITDA
- -5.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -122.99%
- ROIC
- -69.66%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-102,024,000 · -43.35%
- EPS
- $-1.62 · -18.25%
- Op Income
- $-104,030,000
- FCF YoY
- -29.58%
Performance & Tape
- 52W High
- $6.24
- 52W Low
- $0.72
- 50D MA
- $2.85
- 200D MA
- $2.79
- Beta
- 2.29
- Avg Volume
- 2.26M
Get TickerSpark's AI analysis on INZY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 25 | Subramanian Sanjay | sell | 180,000 |
| Jul 1, 25 | Subramanian Sanjay | sell | 135,000 |
| Jul 1, 25 | Subramanian Sanjay | sell | 145,000 |
| Jul 1, 25 | Subramanian Sanjay | other | 39,701 |
| Jul 1, 25 | Subramanian Sanjay | sell | 38,500 |
| Jul 1, 25 | Winton Matthew | sell | 145,000 |
| Jul 1, 25 | Winton Matthew | other | 21,743 |
| Jul 1, 25 | Winton Matthew | sell | 41,500 |
| Jul 1, 25 | Bolte Axel | other | 423,926 |
| Jul 1, 25 | Bolte Axel | sell | 234,176 |
Our INZY Coverage
We haven't published any research on INZY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INZY Report →